BioSpace News Archive

How to Handle Time Off When You Work from Home and Can’t Travel

It’s easy to feel guilty about taking time off when you’re working from home and not physically going on vacation. But your brain needs that vacation.

February 11, 2021

·

2 min read

·

Laura Brothers

Drug Development

Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program

The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.

February 11, 2021

·

3 min read

·

Mark Terry

Genetown

Study: Exhaled COVID-19 Aerosol Droplets Dictated by Age, Infection and Body Mass Index

An observational study published in the Proceedings of the National Academy of Sciences suggests there is a strong positive association between the number of coronavirus disease 2019 (COVID-19) aerosol droplets an individual breathes out with age, infection and body weight.

February 11, 2021

·

3 min read

·

Brandon May

Drug Development

COVID-19 Vaccine Program Hiccups, Misses and Disasters

There are some big surprises among the list of major players in the vaccine space who either dropped their programs or have been significantly delayed.

February 11, 2021

·

5 min read

·

Mark Terry

Career Advice

6 Tips for Finding Work During the Coronavirus Pandemic

Let’s review the six tips for finding work during the coronavirus pandemic.

February 11, 2021

·

4 min read

·

Don Potochny

Bio NC

Precision’s Stealth Cell Allogeneic CAR T Candidate Engineered for Persistence

Precision BioSciences recently received a notice of allowance for a new patent for PBCAR19B, its stealth cell, CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma.

February 11, 2021

·

4 min read

·

Gail Dutton

Business

Immunai Gets Series A Funding for Genomics Database Advancements

Immunai today announced it has received $60 million in Series A funding, bringing its total funding since inception in December 2018 to $80 million.

February 11, 2021

·

4 min read

·

Gail Dutton

Drug Development

AstraZeneca Touts Profits While Slashing Programs

In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.

February 11, 2021

·

3 min read

·

Alex Keown

FDA

FDA Makes Landmark Approval for ANGPTL-3 Inhibitors

The U.S. FDA approved Regeneron’s monoclonal antibody Evkeeza (evinacumab-dgnb) as an add-on treatment for adult and pediatric patients ages 12 and above with homozygous familial hypercholesterolemia (HoFH).

February 11, 2021

·

3 min read

·

Alex Keown

Drug Development

New Vaccine Formulation Shows Promise for Alzheimer’s Target

Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.

February 11, 2021

·

3 min read

·

Mark Terry